O-(2-[¹⁸F]Fluorethyl)-L-Tyrosin (FET) in der Diagnostik von Hirntumoren

Zusammenfassung

Die Positronen-Emissions-Tomografie (PET) mit radioaktiv markierten Aminosäuren hat sich in zahlreichen Studien als sehr leistungsfähig erwiesen, um die Diagnostik von zerebralen Gliomen zu verbessern. Die Magnetresonanztomografie (MRT) ist als Verfahren der ersten Wahl zur Diagnostik von zerebralen Gliomen unumstritten, erlaubt jedoch in vielen Situationen nur eine eingeschränkte Differenzierung des Tumorgewebes von unspezifischen Gewebsveränderungen. Die Aminosäure O-(2-[¹⁸F]Fluorethyl)-L-Tyrosin (FET) ist ein neuer PET-Tracer, der wie [¹⁸F]-Fluordeoxyglukose (FDG) in großen Mengen hergestellt werden kann und damit für den breiten klinischen Einsatz geeignet ist. Die FET-PET bietet eine spezifischere Darstellung der Lokalisation und Ausdehnung des soliden Gliomgewebes als die MRT, was bei der Planung einer Biopsie, eines neurochirurgischen Eingriffs und einer Bestrahlung sehr hilfreich sein kann. Des Weiteren können Tumorrezidive von posttherapeutischen Veränderungen mit hoher Spezifität differenziert, wertvolle prognostische Informationen bei niedriggradigen Gliomen gewonnen und Therapieeffekte frühzeitig beurteilt werden.

Abstract

Positron emission tomography (PET) using radiolabeled amino acids has shown great potential for a more accurate diagnosis of cerebral gliomas. Magnetic resonance imaging (MRI) is the investigation of choice for diagnosing cerebral glioma, but its capacity to differentiate tumor tissue from non-specific tissue changes is limited. ([¹⁸F] Fluoroethyl)-L-tyrosine (FET) is a new tracer for PET that can be produced with high efficiency and distributed on a wide clinical scale like [¹⁸F]-Fluorodeoxyglucose (FDG). The use of FET PET allows better delineation of tumor margins and improves targeting of biopsy and radiotherapy, and planning surgery. In addition, amino acid imaging appears useful in distinguishing tumor recurrence from non-specific post-therapeutic scar tissue, predicting prognosis in low grade gliomas, and monitoring metabolic response during treatment.

Schlüsselwörter

Aminosäure-PET - Hirntumoren - O-(2-[¹⁸F]Fluorethyl)-L-Tyrosin (FET)

Key words

amino acid PET - brain tumors - O-(2-[¹⁸F]Fluorethyl)-L-tyrosine (FET)

Literatur

• 1 Floeth FW, Pauleit D, Wittsack HJ. et al . Multimodal metabolic imaging of cerebral gliomas using positron emission tomography with [¹⁸F]-fluoroethyl-l-tyrosine and magnetic resonance spectroscopy.  J Neurosurgery. 2005;  102 318-327
• 2 Floeth FW, Pauleit D, Sabel M. et al . ¹⁸F-FET PET Differentiation of ring enhancing brain lesions.  J Nucl Med. 2006;  47 776-782
• 3 Floeth FW, Pauleit D, Sabel M. et al . Prognostic value of O-(2-¹⁸F-fluoroethyl)-L-tyrosine PET and MRI in low-grade glioma.  J Nucl Med. 2007;  48 519-527
• 4 Floeth FW, Sabel M, Stoffels G. et al . Prognostic value of O-(2-[¹⁸F]fluoroethyl)-L-tyrosine PET and MRI in small unspecific incidental brain lesions with suspicion of low grade glioma.  J Nucl Med. 2008;  49 730-737
• 5 Grosu AL, Weber WA, Franz M. et al . Reirradiation of recurrent high-grade gliomas using amino acid PET(SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy.  Int J Radiat Oncol Biol Phys. 2005;  63 511-519
• 6 Hamacher K, Coenen HH. Efficient routine production of the ¹⁸F-labelled amino acid O-(2-[¹⁸F]fluoroethyl)-L-tyrosine.  Appl Radiat Isot. 2002;  57 853-856
• 7 Heiss P, Mayer S, Herz M. et al . Investigation of transport mechanism and uptake kinetics of O-(2-[¹⁸F]fluoroethyl)-L-tyrosine in vitro and in vivo.  J Nucl Med. 1999;  40 1367-1373
• 8 Kaim AH, Weber B, Kurrer MO. et al . (18)F-FDG and (18)F-FET uptake in experimental soft tissue infection.  Eur J Nucl Med Mol Imaging. 2002;  29 648-654
• 9 Laïque S, Egrise D, Monclus M. et al . L-amino acid load to enhance PET differentiation between tumor and inflammation: an in vitro study on (18)F-FET uptake.  Contrast Media Mol Imaging. 2006;  1 212-220
• 10 Langen KJ, Pauleit D, Coenen HH. [¹²³I]Iodo-α-Methyl-L-Tyrosine: uptake mechanisms and clinical applications.  Nucl Med Biol. 2002;  29 625-631
• 11 Langen KJ, Jarosch M, Muhlensiepen H. et al . Comparison of fluorotyrosines and methionine uptake in F98 rat gliomas.  Nucl Med Biol. 2003;  30 501-508
• 12 Langen KJ, Hamacher K, Weckesser M. et al . O-(2-[¹⁸F]fluoroethyl)-L-tyrosine: uptake mechanisms and clinical applications.  Nucl Med Biol. 2006;  33 287-294
• 13 Langen KJ, Stoffels G. Hirntumoren.  Nuklearmediziner. 2007;  30 204-211
• 14 Langen KJ, Tatsch K, Grosu AL. et al . Diagnostik von zerebralen Gliomen mit radioaktiv markierten Aminosäuren.  Dtsch Arztebl. 2008;  105 55-61
• 15 Mehrkens JH, Pöpperl G, Rachinger W. et al . The positive predictive value of O-(2-[¹⁸F]fluoroethyl)-L-tyrosine (FET) PET in the diagnosis of a glioma recurrence after multimodal treatment.  J Neurooncol. 2008;  88 27-35
• 16 Messing-Jünger AM, Floeth FW, Pauleit D. et al . Multimodal target point assessment for atereotactic biopsy in children with diffuse bithalamic astrocytomas.  Childs Nerv Syst. 2002;  18 445-449
• 17 Pauleit D, Floeth F, Herzog H. et al . Whole-body distribution and dosimetry of O-(2-[¹⁸F]fluoroethyl)-L-tyrosine.  Eur J Nucl Med Mol Imaging. 2003;  30 519-524
• 18 Pauleit D, Floeth F, Tellmann L. et al . Comparison of O-(2-[¹⁸F]fluoro-ethyl)-L-tyrosine (FET) PET and 3-[¹²³I]Iodo-α-Methyl-L-tyrosine (IMT) SPECT in brain tumors.  J Nucl Med. 2004;  45 374-381
• 19 Pauleit D, Floeth F, Hamacher K. et al . O-(2-[¹⁸F]fluoroethyl)-L-tyrosine PET combined with Magnetic Resonance Imaging Improves the Diagnostic Assessment of Cerebral Gliomas.  Brain. 2005;  128 678-687
• 20 Pauleit D, Stoffels G, Schaden W. et al . PET with O-(2-[¹⁸F]fluoroethyl)-L-tyrosine (FET) in peripheral tumors: First clinical Results.  J Nucl Med. 2005;  46 411-416
• 21 Pauleit D, Zimmermann A, Stoffels G. et al . FET PET compared with FDG PET and CT in patients with head-neck cancers.  J Nucl Med. 2006;  47 256-261
• 22 Pöpperl G, Gotz C, Rachinger W. et al . Value of O-(2-[¹⁸F]fluoroethyl)- L-tyrosine PET for the diagnosis of recurrent glioma.  Eur J Nucl Med Mol Imaging. 2004;  31 1464-1470
• 23 Pöpperl G. PET (und PET/CT) – Stellenwert in der Diangostik von primären Hirntumore.  Nuklearmediziner. 2004;  27 246-254
• 24 Pöpperl G, Goldbrunner R, Gildehaus FJ. et al . O-(2-[(18)F]fluoroethyl)-L-tyrosine PET for monitoring the effects of convection-enhanced delivery of paclitaxel in patients with recurrent glioblastoma.  Eur J Nucl Med Mol Imaging. 2005;  32 1018-1025
• 25 Pöpperl G, Gotz C, Rachinger W. et al . Serial O-(2-[(18)F]fluoroethyl)-L-tyrosine PET for monitoring the effects of intracavitary radioimmunotherapy in patients with malignant glioma.  Eur J Nucl Med Mol Imaging. 2006;  33 792-800
• 26 Pöpperl G, Kreth FW, Herms J. et al . Analysis of ¹⁸F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods?.  J Nucl Med. 2006;  47 393-403
• 27 Pöpperl G, Kreth FW, Mehrkens JH. et al . FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading.  Eur J Nucl Med Mol Imaging. 2007;  34 1933-1942
• 28 Rachinger W, Goetz C, Pöpperl G. et al . Positron emission tomography with O-(2-[¹⁸F]fluoroethyl)-l-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas.  Neurosurgery. 2005;  57 505-511
• 29 Rau FC, Weber WA, Wester HJ. et al . O-(2-[¹⁸F]Fluoroethyl)-L-tyro-sine (FET): a tracer for differentiation of tumour from inflamma-tion in murine lymph nodes.  Eur J Nucl Med Mol Imaging. 2002;  29 1039-1046
• 30 Salber D, Stoffels G, Pauleit D. et al . Differential uptake of ¹⁸F-FET, ³H-L-methionine and ³H-deoxyglucose in brain abscesses.  J Nucl Med. 2007;  48 2056-2062
• 31 Salber D, Stoffels G, Pauleit D. et al . Differential uptake of ¹⁸F-FET and ³H-L-methionine in focal cortical ischemia.  Nucl Med Biol. 2006;  33 1029-1035
• 32 Spaeth N, Wyss MT, Weber B. et al . Uptake of ¹⁸F-fluorocholine, ¹⁸F-fluoroethyl-L-tyrosine, and ¹⁸F-FDG in acute cerebral radiation injury in the rat: implications for separation of radiation necrosis from tumor recurrence.  J Nucl Med. 2004;  45 1931-1938
• 33 Spaeth N, Wyss MT, Pahnke J. et al . Uptake of 18F-fluorocholine, 18F-fluoro-ethyl-L: -tyrosine and 18F-fluoro-2-deoxyglucose in F98 gliomas in the rat.  Eur J Nucl Med Mol Imaging. 2006;  33 673-682
• 34 Stadlbauer A, Prante O, Nimsky C. et al . Metabolic imaging of cerebral gliomas: spatial correlation of changes in O-(2-18F-fluoroethyl)-L-tyrosine PET and proton magnetic resonance spectroscopic imaging.  J Nucl Med. 2008;  49 721-729
• 35 Stöber B, Tanase U, Herz M. et al . Differentiation of tumour and inflammation: characterisation of [methyl-3H]methionine (MET) and O-(2-[¹⁸F]fluoroethyl)-L-tyrosine (FET) uptake in human tumour and inflammatory cells.  Eur J Nucl Med Mol Imaging. 2006 Aug;  33 ((8)) 932-939
• 36 Stockhammer F, Plotkin M, Amthauer H. et al . Correlation of F-18-fluoro-ethyl-tyrosin uptake with vascular and cell density in non-contrast-enhancing gliomas.  J Neurooncol.. 2008;  88 205-210
• 37 Vees H, Senthamizhchelvan S, Miralbell R. et al . Assessment of various strategies for (18)F-FET PET-guided delineation of target volumes in high-grade glioma patients.  Eur J Nucl Med Mol Imaging. 2008 Sep;  26 , [Epub ahead of print]
• 38 Weber WA, Wester HJ, Grosu AL. et al . O-(2-[¹⁸F]Fluoroethyl)-L-tyrosine and L-[methyl-¹¹C]methionine uptake in brain tumours: initial results of a comparative study.  Eur J Nucl Med. 2000;  27 542-549
• 39 Weckesser M, Langen KJ, Rickert CH. et al . Initial experiences with O-(2-[¹⁸F]fluorethyl)-L-tyrosine PET in the evaluation of primary brain tumors.  Eur J Nucl Med. 2005;  32 422-429
• 40 Wester HJ, Herz M, Weber W. et al . Synthesis and radiopharmacology of O-(2-[¹⁸F]fluoroethyl)-L-tyrosine for tumor imaging.  J Nucl Med. 1999;  40 205-212
• 41 Wyss MT, Hofer S, Hefti M. et al . Spatial heterogeneity of low-grade gliomas at the capillary level: a PET study on tumor blood flow and amino acid uptake.  J Nucl Med. 2007;  48 1047-1052

Korrespondenzadresse